[Research progress on bisphosphonate-related osteonecrosis of the jaws]

Hua Xi Kou Qiang Yi Xue Za Zhi. 2017 Feb 1;35(1):29-36. doi: 10.7518/hxkq.2017.01.004.
[Article in Chinese]

Abstract

Bisphosphonates (BPs), as potent drugs inhibiting bone resorption, have been widely used for treatment of several diseases. In recent years, dentists and oral and maxillofacial surgeons reported continuously increasing cases of bisphosphonate-related osteonecrosis of the jaws (BRONJ). This disease is clinically characterized by exposed bones, formation of sequestrum, pain, and halitosis. Provided that pathogenesis of BRONJ is unclear, effective treatments for this disease are currently unavailable. Thus, prevention plays an important role in the management of BRONJ. This review summarizes research progress on pathogenesis, risk factors, clinical characteristics, treatment, and prevention of this condition.

双膦酸盐类(BPs)药物是一种强有力的骨吸收抑制剂,已广泛应用于临床治疗中。近年来,有关双膦酸盐相关性骨坏死(BRONJ)的报道日渐增多,该病临床上以骨面裸露、死骨形成、疼痛、口臭等为特征。由于目前发病机理不明确,临床上尚无完全有效的治疗方法,因此BRONJ的预防十分重要。本文就BRONJ的发病机制、危险因素、临床特征、治疗预后等方面的研究现状进行阐述,以期为临床提供帮助。.

Keywords: bisphosphonates; jaws; osteonecrosis.

Publication types

  • Review

MeSH terms

  • Bisphosphonate-Associated Osteonecrosis of the Jaw*
  • Bone Density Conservation Agents
  • Bone Resorption
  • Diphosphonates
  • Humans
  • Jaw
  • Risk Factors
  • Treatment Outcome

Substances

  • Bone Density Conservation Agents
  • Diphosphonates